Cancer remains a major global health issue, with millions affected by metastatic and refractory diseases. Current treatments often lack personalized strategies, leading to trial-and-error approaches that delay effective treatment and increase patient suffering, with 2 out of 3 cases affected by ineffective therapies. BioReperias ZTX platform addresses this gap by providing a fast, accurate solution for predicting treatment outcomes through its proprietary Zebrafish Tumor Xenograft (ZTX) technology, ZTX PREDICT. Unlike conventional molecular profiling, our solution delivers results in just five days, with up to 80% accuracy in predicting treatment success and metastasis risk, offering a breakthrough in personalized medicine for 90% of patients. This innovative approach allows doctors to make faster, more informed decisions, improving survival rates, reducing healthcare costs, and supporting pharma in designing clinical trials. Over the past years, BioReperia has collaborated with leading pharmaceutical companies, hospitals, and research institutions in pre-clinical drug efficacy studies using its platform, becoming a recognized leader in zebrafish-based cancer modeling. Now, after proving the effectiveness of the ZTX platform, ZTX PREDICT, for its use in individualized cancer medicine and treatment outcome prediction through small proof-of-concept clinical trials for 3 indications, and having developed two robotic systems and AI-imaging software to automate our IVD service, we are in position to scale our capacities by tenfold by refining the state-of-the art infrastructure, and conduct large clinical trials to provide robustness of ZTX PREDICT. Once we complete the final development, the compliance with the EU-IVR regulation and scale-up our ISO-lab, we will be ready to global leader in personalized medicine and expand our IVD services to Europe and USA leading to 5-years cumulative revenues of >73M and a company value creation of 500M by 2033.